Authors: Adenis, A Bonneterre, J Bonneterre, ME Pion, JM Vanlemmens, L Gladieff, L de Lafontan, B Martel, P Mihura, J Roche, H Gedouin, D Kerbrat, P Lesimple, T Bremond, A Devaux, Y Delecroix, V Fumoleau, P Maugard-Louboutin, C Namer, M Goudier, MJ Morice, F Montcuquet, P Schraub, S Coudert, B Fargeot, P de Gislain, C Mayer, F Bastit, P Chevallier, B Grandgirard, A Monnier, A Sun, X Clavere, P Ollivier, JP Rhein, B Roullet, B Datchary, J Audhuy, B Barats, JC Kohser, F Dides, S Ramos, R Cattan, A Eymard, JC Pourny, C Weber, B de Laroche, G Pichon, A Seffert, P Hayat, M Zambon, E Chollet, P Van Praagh, I

Citation: A. Adenis et al., Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French adjuvant study group 05 randomized trial, J CL ONCOL, 19(3), 2001, pp. 602-611

Authors: Belpomme, D Gauthier, S Pujade-Lauraine, E Facchini, T Goudier, MJ Krakowski, I Netter-Pinon, G Frenay, M Gousset, C Marie, FN Benmiloud, M Sturtz, F

Citation: D. Belpomme et al., Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma, ANN ONCOL, 11(11), 2000, pp. 1471-1476

Authors: Bastit, P Chevallier, B Chevreau, C Mihura, J Roche, H Namer, M Gedouin, D Kerbrat, P Lesimple, T Coudert, B Fargeot, P de Gislain, C Mayer, F Luporsi, E Rios, M Weber, B Bremond, A Devaux, Y Monteuquet, P Schraub, S Hayat, M Zambon, E Grandgirard, A Monnier, A Sun, X Clavere, P Ollivier, JP Rhein, B Roullet, B Chollet, P Van Praagh, I Cattan, A Eymard, JC Pourny, C Facchini, T Walter, S Dides, S Ramos, R Guiochet, N Seffert, P Perpoint, X Sztermer, JF Cretin, J Goudier, MJ Morice, F Delecroix, V Fumoleau, P

Citation: P. Bastit et al., Epirubicin-based chemotherapy in metastatic breast cancer patients: Role of dose-intensity and duration of treatment, J CL ONCOL, 18(17), 2000, pp. 3115-3124